BioAlliance Receives European Approval For Loramyc Tablet

BioAlliance has received European approval for embossing Loramyc mucoadhesive buccal tablet, for the treatment of oropharyngeal candidiasis.

The embossing process has been approved under the Mutual Recognition Procedure. It was first required for the US market, where BioAlliance submitted a new drug application for Loramyc to the FDA in June 2009.

BioAlliance Pharma also received European approval for extension of Loramyc’s shelf life from 18 to 36 months.

The company said that these two key industrial parameters are complementary assets for Loramyc and will help optimizing manufacturing, storage and distribution costs.

BioAlliance develops and markets products in France, especially in the fields of opportunistic infections and chemotherapy complications.